All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The allelic burden in patients with acute myeloid leukemia (AML) post allogeneic hematopoietic stem cell transplantation (HCT) has not been longitudinally studied yet. A group of researchers from the University of Toronto, Toronto, ON, Canada, investigated the feasibility and the prognostic value of post-transplant monitoring using next-generation sequencing (NGS) in patients with AML undergoing allogeneic HCT. The results were published in Blood this month.
In this study, bone marrow samples from 104 patients (median age = 42 years; range, 15–63) with AML who underwent allogeneic HCT between January 2004 and November 2015 were analyzed using NGS. Samples were analyzed at the time of diagnosis, pre-HCT, and day 21 post-HCT. At Day 21 post-HCT, variant allele frequency (VAF) ≥ 0.2% (minimum VAF was 0.02) grouped 88 patients (84.6%) as low VAF group and 16 (15.4%) as high VAF group.
In summary, this is the first study to investigate the feasibility of post-transplant monitoring in AML using NGS. The study demonstrates that “post-transplant NGS monitoring on serial samples taken after induction chemotherapy and after allogeneic HCT reveals stepwise clearance of allelic burden from initial AML clone”. Additionally, the presence of allelic burden day 21 post-HCT is prognostic for relapse and survival.
The researchers concluded by stating that their “data and analysis demonstrated NGS-based monitoring of AML patients receiving allogeneic HCT provides valuable information and needs to be combined with the baseline mutational profile and clinical evaluation to predict post-transplant outcome and mortality”.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox